192 related articles for article (PubMed ID: 3862071)
1. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
Marie JP; Thevenin D; Zittoun R
Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
[TBL] [Abstract][Full Text] [Related]
2. Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin.
Nara N; Yamashita Y; Murohashi I; Tanikawa S; Imai Y; Aoki N
Cancer Res; 1987 May; 47(9):2376-9. PubMed ID: 3471325
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Gustavsson A; Olofsson T
Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
[TBL] [Abstract][Full Text] [Related]
4. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
[TBL] [Abstract][Full Text] [Related]
6. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
7. Drug sensitivity test for acute myeloblastic leukemia by an efficient leukemic blast colony assay using 5637-conditioned medium as a stimulator.
Asano Y; Okamura S; Shibuya T; Morioka E; Harada M; Akazawa K; Niho Y
J Med; 1990; 21(6):289-99. PubMed ID: 2093096
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
Marie JP; Zittoun R; Delmer A; Thevenin D; Suberville AM
Leukemia; 1987 Feb; 1(2):121-6. PubMed ID: 3478535
[TBL] [Abstract][Full Text] [Related]
10. [Survey of anthracyclines derivatives in haematology (author's transl)].
Jacquillat C; Weil M; Auclerc MF; Maral J; Schaison G; Boiron M; Bernard J
Nouv Presse Med; 1978 Jun; 7(23):2061-6. PubMed ID: 673774
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Marsh JC; Brown BJ; Nierenburg MM
Cancer Res; 1983 Jun; 43(6):2962-6. PubMed ID: 6573955
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 and 2 trial of rubidazone in patients with acute leukemia.
Benjamin RS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Cancer Res; 1977 Dec; 37(12):4623-8. PubMed ID: 270389
[No Abstract] [Full Text] [Related]
13. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
Bickers J; Benjamin R; Wilson H; Eyre H; Hewlett J; McCredie K
Cancer Treat Rep; 1981; 65(5-6):427-30. PubMed ID: 6940659
[TBL] [Abstract][Full Text] [Related]
14. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).
Jensen PB; Vindeløv L; Roed H; Demant EJ; Sehested M; Skovsgaard T; Hansen HH
Br J Cancer; 1989 Dec; 60(6):838-44. PubMed ID: 2574988
[TBL] [Abstract][Full Text] [Related]
16. Development of drug resistance in cultured clonogenic leukemic blast cells during the clinical course of myeloblastic leukemia.
Asano Y; Okamura S; Shibuya T; Morioka E; Hirota Y; Niho Y
Oncology; 1989; 46(5):339-42. PubMed ID: 2779949
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
18. [Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Shimazaki C; Nakajima Y; Ura Y; Hamami T; Haruyama H; Isemura T; Nakagawa M; Ijichi H
Rinsho Ketsueki; 1981 Jul; 22(7):1116-22. PubMed ID: 6948970
[No Abstract] [Full Text] [Related]
19. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G; Zimmermann M; Janka-Schaub G;
Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
[TBL] [Abstract][Full Text] [Related]
20. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
